Reuters logo
BRIEF-Ortho Dermatologics, unit of Valeant, announces two-year findings from pivotal phase 3 study of Siliq injection data demonstrating long-term efficacy profile
2017年10月12日 / 中午12点27分 / 10 天前

BRIEF-Ortho Dermatologics, unit of Valeant, announces two-year findings from pivotal phase 3 study of Siliq injection data demonstrating long-term efficacy profile

Oct 12 (Reuters) - Valeant Pharmaceuticals International Inc

* Ortho Dermatologics announces two-year findings from pivotal phase 3 study of Siliq™ (brodalumab) injection data demonstrating long-term efficacy profile

* Ortho Dermatologics​ - ‍Over a two-year trial, a pasi 100 response rate was reached by 59 percent of a sub-analysis group of patients

* ‍ortho Dermatologics - At week 120, siliq continued to be generally well-tolerated with safety profile comparable to that observed in 52-week period​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below